Mirum Pharmaceuticals' Breakthrough in Rare Liver Disease Treatment

Mirum Pharmaceuticals announced that its experimental drug, volixibat, succeeded in a mid-stage study by alleviating severe itching in patients with a rare liver disease. The study involved 158 participants, with a focus group of 111 experiencing moderate to severe symptoms. The results signify a promising development in treatment options.

Mirum Pharmaceuticals has reported a notable success in testing volixibat, an experimental drug aimed at treating severe itching in patients with a rare liver disease. In a mid-stage study involving 158 participants, volixibat effectively reduced pruritus in those with more critical symptoms.

The study's primary analysis concentrated on a subset of 111 patients who experienced moderate to severe itching, with the drug being administered at a dosage of 20 mg twice daily. A separate assessment was conducted for an additional group of 47 patients suffering from milder cases.

The positive outcomes from this trial offer encouraging indications for future treatment options in rare liver disease management, marking an important milestone for Mirum Pharmaceuticals in the field of biopharmaceutical research and development.